GSK vet Antony Blanc signs on to become CureVac's CBO and CCO; Chris Cabell out, Paul Streck in as Arena Pharmaceuticals CMO
→ Enthused about the Phase I data for their Covid-19 mRNA vaccine and believing they’ve cracked the cold-storage code in delivering them, CureVac has brought Antony Blanc into the fray as CBO and chief commercial officer. While at GSK from 2009-17, Blanc served in several capacities with GSK Vaccines, including as integration lead when the pharma giant acquired Novartis Vaccines in 2015. Before his time at GSK, Blanc was CBO at Synosia Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.